agomelatine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
99 138112-76-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • S20098
  • S-20098
  • agomelatine
  • valdoxan
  • thymanax
an antidepressant, it works by stimulating the MT1 and MT2 receptors, which are normally activated by melatonin, and also by blocking the 5-HT2C receptors, which are normally activated by the neurotransmitter 5-hydroxytryptamine
  • Molecular weight: 243.31
  • Formula: C15H17NO2
  • CLOGP: 2.11
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 1
  • TPSA: 38.33
  • ALOGS: -4.50
  • ROTB: 4

Drug dosage:

DoseUnitRoute
25 mg O

ADMET properties:

PropertyValueReference
fu (Fraction unbound in plasma) 0.07 % Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Approvals:

DateAgencyCompanyOrphan
Feb. 19, 2009 EMA Les Laboratoires Servier

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Lipoedema 50.54 30.12 9 2567 289 63486157
Drug interaction 48.92 30.12 53 2523 229078 63257368
Selective eating disorder 47.64 30.12 12 2564 2060 63484386
Extrapyramidal disorder 45.75 30.12 18 2558 13266 63473180
Intentional overdose 44.47 30.12 31 2545 74121 63412325
Serum serotonin increased 40.17 30.12 7 2569 198 63486248
Salivary hypersecretion 39.64 30.12 14 2562 7652 63478794
Suicidal ideation 39.55 30.12 27 2549 62394 63424052
Fistula discharge 38.88 30.12 9 2567 1084 63485362
Spinal cord disorder 37.46 30.12 9 2567 1272 63485174
Intentional self-injury 37.26 30.12 19 2557 25668 63460778
Hyponatraemia 35.18 30.12 32 2544 111868 63374578
Accelerated hypertension 34.53 30.12 7 2569 452 63485994
Bladder spasm 34.48 30.12 9 2567 1779 63484667
Spinal pain 32.32 30.12 14 2562 13125 63473321
Sleep deficit 32.04 30.12 7 2569 649 63485797
Psychiatric decompensation 31.64 30.12 8 2568 1393 63485053
Urinary tract infection enterococcal 30.76 30.12 9 2567 2704 63483742
Urinary incontinence 30.67 30.12 18 2558 31996 63454450
Myelopathy 30.40 30.12 9 2567 2817 63483629

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Tachycardia 43.25 39.87 32 1379 84740 34870780

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug interaction 81.50 26.90 96 3454 415087 79325751
Intentional overdose 48.27 26.90 39 3511 105921 79634917
Tachycardia 44.86 26.90 47 3503 177721 79563117
Hyponatraemia 41.31 26.90 45 3505 177803 79563035
Suicide attempt 38.76 26.90 31 3519 82901 79657937
Anorgasmia 36.81 26.90 9 3541 1245 79739593
Serum serotonin increased 36.19 26.90 7 3543 323 79740515
Drug level increased 35.33 26.90 22 3528 39629 79701209
Sleep disorder 33.73 26.90 29 3521 85648 79655190
Lipoedema 32.47 26.90 6 3544 216 79740622
Extrapyramidal disorder 29.25 26.90 16 3534 22663 79718175
Acute stress disorder 28.32 26.90 6 3544 438 79740400
Drug ineffective 27.13 26.90 107 3443 1080806 78660032
Salivary hypersecretion 26.94 26.90 13 3537 14211 79726627

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N06AX22 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTIDEPRESSANTS
Other antidepressants
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D006993 Hypnotics and Sedatives

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Major depressive disorder indication 370143000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 12.7 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
5-hydroxytryptamine receptor 2C GPCR ANTAGONIST Ki 6.20 IUPHAR DRUG LABEL
Melatonin receptor type 1A GPCR AGONIST Ki 10.22 CHEMBL DRUG LABEL
Melatonin receptor type 1B GPCR AGONIST Ki 10 CHEMBL DRUG LABEL
5-hydroxytryptamine receptor 2A GPCR ANTAGONIST Ki 5.40 IUPHAR
5-hydroxytryptamine receptor 2B GPCR ANTAGONIST Ki 6.60 IUPHAR
Melatonin receptor GPCR Ki 10 CHEMBL
Melatonin receptor GPCR Ki 9.28 CHEMBL

External reference:

IDSource
D02578 KEGG_DRUG
C0971637 UMLSCUI
CHEBI:134990 CHEBI
CHEMBL10878 ChEMBL_ID
DB06594 DRUGBANK_ID
C084711 MESH_SUPPLEMENTAL_RECORD_UI
82148 PUBCHEM_CID
198 IUPHAR_LIGAND_ID
7392 INN_ID
137R1N49AD UNII
698012009 SNOMEDCT_US
702952002 SNOMEDCT_US
AWY PDB_CHEM_ID
013126 NDDF

Pharmaceutical products:

None